scholarly journals Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient

Diagnostics ◽  
2017 ◽  
Vol 7 (4) ◽  
pp. 61
Author(s):  
Christos Sachpekidis ◽  
Antonia Dimitrakopoulou-Strauss ◽  
Stefan Delorme ◽  
Hartmut Goldschmidt
Keyword(s):  
Multiple Myeloma ◽  
Diffusion Weighted Imaging ◽  
Early Response ◽  
Response Evaluation ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
And Diffusion

18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement

2015 ◽  
Vol 40 (11) ◽  
pp. 873-876 ◽  
Author(s):  
Aylin Oral ◽  
Bulent Yazici ◽  
Özgür Ömür ◽  
Melda Comert ◽  
Guray Saydam
Keyword(s):  
Multiple Myeloma ◽  
Thyroid Cartilage ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Ct Findings ◽  
Pet Ct ◽  
18F Fdg

Het gebruik van 18F-FDG PET/CT ter evaluatie van multipel myeloom

2021 ◽  
Author(s):  
K. VOET ◽  
B. VAN DEN BROECK ◽  
I. GOETHALS ◽  
F. OFFNER
Keyword(s):  
Multiple Myeloma ◽  
Fdg Pet ◽  
Total Lesion Glycolysis ◽  
Classification Systems ◽  
Bone Lesions ◽  
Response Evaluation ◽  
Reliable Technique ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

The use of 18F-FDG PET/CT to evaluate patients with multiple myeloma. Detection of bone lesions are important to diagnose multiple myeloma. In this study we investigate the role of an 18F-FDG PET/CT exam. Fifteen newly diagnosed multiple myeloma patients were included in this retrospective study. A 18F-FDG PET/CT was performed at diagnosis and after induction therapy. The response of a treatment is examined by semi-quantitative parameters (standardised 18F-FDG uptake values) and volumetric parameters (metabolic tumor volume and total lesion glycolysis). The aim of this study is to evaluate the use of these parameters for response evaluation and risk assessment in multiple myeloma. The prognostic value of an increased metabolic activity of the spleen is also examined. All semi-quantitative and volumetric parameters in this study are useful for response evaluation. Lower values of maximum or mean standardized uptake values (SUVmax, SUVmean) and total lesion glycolysis at diagnosis are prognostic favourable. We could not prove prognostic relevance for a spleen to liver ratio. Due to the small study population, all these results have to be confirmed in a larger patient cohort. 18F-FDG PET/CT is a reliable technique for response evaluation and risk stratification in multiple myeloma. In the future semi-quantitative and volumetric parameters will probably be incorporated in the risk classification systems of multiple myeloma patients.

scholarly journals 18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non–Small Cell Lung Cancer Patients: A Comparison of Assessment Methods

2017 ◽  
Vol 58 (12) ◽  
pp. 1931-1937 ◽  
Author(s):  
Joan Fledelius ◽  
Anne Winther-Larsen ◽  
Azza A. Khalil ◽  
Catharina M. Bylov ◽  
Karin Hjorthaug ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Early Response ◽  
Small Cell ◽  
Response Evaluation ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art

2020 ◽  
Vol 13 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Angelo Castello ◽  
Egesta Lopci
Keyword(s):  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Evaluation Criteria ◽  
Advanced Melanoma ◽  
Response Criteria ◽  
Response Evaluation ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Background: Immune checkpoint inhibitors (ICI) have achieved astonishing results and improved overall survival (OS) in several types of malignancies, including advanced melanoma. However, due to a peculiar type of anti-cancer activity provided by these drugs, the response patterns during ICI treatment are completely different from that with “old” chemotherapeutic agents. Objective: To provide an overview of the available literature and potentials of 18F-FDG PET/CT in advanced melanoma during the course of therapy with ICI in the context of treatment response evaluation. Methods: Morphologic criteria, expressed by Response Evaluation Criteria in Solid Tumors (RECIST), immune-related response criteria (irRC), irRECIST, and, more recently, immune-RECIST (iRECIST), along with response criteria based on the metabolic parameters with 18F-Fluorodeoxyglucose (18FFDG), have been explored. Results: To overcome the limits of traditional response criteria, new metabolic response criteria have been introduced on time and are being continuously updated, such as the PET/CT Criteria for the early prediction of Response to Immune checkpoint inhibitor Therapy (PECRIT), the PET Response Evaluation Criteria for Immunotherapy (PERCIMT), and “immunotherapy-modified” PET Response Criteria in Solid Tumors (imPERCIST). The introduction of new PET radiotracers, based on monoclonal antibodies combined with radioactive elements (“immune-PET”), are of great interest. Conclusion: Although the role of 18F-FDG PET/CT in malignant melanoma has been widely validated for detecting distant metastases and recurrences, evidences in course of ICI are still scarce and larger multicenter clinical trials are needed.

scholarly journals Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma

2021 ◽  
Author(s):  
Olwen Westerland ◽  
◽  
Ashik Amlani ◽  
Christian Kelly-Morland ◽  
Michal Fraczek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Data ◽  
Bone Disease ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Bone Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. Methods Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. Results Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). Conclusion Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

Sign in / Sign up

Export Citation Format

Share Document